Ann: SPL receives positive FDA feedback on DEP SN38 for PROC, page-16

I hope a deal isn't " imminent "as frankly it wouldn't be a good one for SPL. If SPL are to get value for shareholder they need to put in more work and management need to earn those big bucks.
Early Days still
I am seeing a few traits in this that I don't like.

I still dislike companies that try and present large numbers and reality is plat res is a 25% ? subset. So - 80,000 worldwide and how many in 1st world that can seek and afford treatment ? - demographics are important . 33% of that top 10 group are in countries that have poor healthcare and large medical poverty knocking the 80,000 number considerably. Always be concerned about stats and numbers that would have had a large part of covid timeline in them as diagnosis was poor and outcomes due to treatment access may have been suboptimal. Annual Stats are probably accurate but many ethical companies are putting in subnotes if there are variances they know about such as covid. Better and earlier diagnosis as is BRCA testing etc

"3Platinum-Resistant Ovarian Cancer | A Patient Group with Significant Unmet NeedIn 2022, there were an estimated 325,000 new cases of ovarian cancer worldwide, and 207,000deaths1. Platinum-resistant and platinum-refractory ovarian cancer are the largest unmet needswithin the ovarian cancer indication. Nearly all patients who have recurrent ovarian cancerbecome resistant to platinum-based therapies, which are the mainstay of initial cancer treatment.Effective treatment options for patients who are platinum-resistant/refractory are limited, and theprognosis is poor."

https://www.wcrf.org/preventing-cancer/cancer-statistics/ovarian-cancer-statistics/